Title
Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression
Authoring Organizations
Publication Month/Year
September 4, 2018
Last Updated Month/Year
October 2, 2024
Supplemental Implementation Tools
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Document Objectives
To provide an updated joint ASCO/Infectious Diseases Society of America (IDSA) guideline on antimicrobial prophylaxis for adult patients with immunosuppression associated with cancer and its treatment.
Target Patient Population
Patients receiving treatment of cancer as inpatients or outpatients who are experiencing immune suppression or increased susceptibility to infection.
Target Provider Population
Oncologists, infectious disease specialists, emergency medicine physicians, nurses, and advanced practice providers
PICO Questions
Does antibacterial prophylaxis with a fluoroquinolone, compared with placebo, no intervention, or another class of antibiotic reduce the incidence of and mortality related to FN?
Does antifungal (antiyeast or antimold) prophylaxis with an oral triazole or parenteral echinocandin, compared with no prophylaxis or another treatment option, reduce the incidence of and mortality related to FN?
Is other prophylaxis, eg, antiviral, more effective than placebo/no treatment for higher-risk immunosuppressed patients with cancer?
Are precautions such as neutropenic diet, etc., more effective than no intervention for prophylaxis of infection in afebrile neutropenic outpatients?
Inclusion Criteria
Male, Female, Adolescent, Adult, Child, Older adult
Health Care Settings
Ambulatory, Hospital, Outpatient
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Management, Prevention
Keywords
cancer, antimicrobial prophylaxis, Cancer-Related Immunosuppression, immunosuppressed patients
Source Citation
DOI: 10.1200/JCO.18.00374 Journal of Clinical Oncology 36, no. 30 (October 20, 2018) 3043-3054.